US6080216A
(en)
*
|
1998-04-22 |
2000-06-27 |
3M Innovative Properties Company |
Layered alumina-based abrasive grit, abrasive products, and methods
|
JPWO2005049622A1
(ja)
*
|
2003-11-19 |
2007-06-07 |
日本たばこ産業株式会社 |
5−5員縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての用途
|
US20070049593A1
(en)
*
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
US7795247B2
(en)
*
|
2004-10-26 |
2010-09-14 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Tetracyclic indole derivatives as antiviral agents
|
CA2585084A1
(en)
*
|
2004-10-26 |
2006-05-04 |
Immacolata Conte |
Tetracyclic indole derivatives as antiviral agents
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
EP1879607B1
(en)
|
2005-05-02 |
2014-11-12 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
RU2008107972A
(ru)
|
2005-08-01 |
2009-09-10 |
Мерк энд Ко., Инк. (US) |
Макроциклические пептиды в качестве ингибиторов ns3-протеазы hcv
|
GB0518390D0
(en)
*
|
2005-09-09 |
2005-10-19 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US7399758B2
(en)
*
|
2005-09-12 |
2008-07-15 |
Meanwell Nicholas A |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
US7473688B2
(en)
*
|
2005-09-13 |
2009-01-06 |
Bristol-Myers Squibb Company |
Indolobenzazepine HCV NS5B inhibitors
|
WO2007092000A1
(en)
*
|
2006-02-06 |
2007-08-16 |
Bristol-Myers Squibb Company |
Inhibitors of hcv replication
|
US7456165B2
(en)
|
2006-02-08 |
2008-11-25 |
Bristol-Myers Squibb Company |
HCV NS5B inhibitors
|
GB0608928D0
(en)
*
|
2006-05-08 |
2006-06-14 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
US7456166B2
(en)
|
2006-05-17 |
2008-11-25 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
US7521443B2
(en)
*
|
2006-05-17 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
CN101443336B
(zh)
*
|
2006-05-17 |
2012-07-04 |
百时美施贵宝公司 |
环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂
|
US7521441B2
(en)
*
|
2006-05-22 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
JP5205370B2
(ja)
*
|
2006-05-25 |
2013-06-05 |
ブリストル−マイヤーズ スクイブ カンパニー |
シクロプロピル縮合インドロベンゾアゼピンhcvns5b阻害剤
|
US7521442B2
(en)
|
2006-05-25 |
2009-04-21 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
US7452876B2
(en)
*
|
2006-06-08 |
2008-11-18 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
KR101512477B1
(ko)
|
2006-07-13 |
2015-04-15 |
아칠리온 파르마세우티칼스 인코포레이티드 |
바이러스 복제 억제제로서 사용되는 4-아미노-4-옥소부타노일 펩티드
|
US20080045498A1
(en)
*
|
2006-07-20 |
2008-02-21 |
Genelabs Technologies, Inc. |
Polycyclic viral inhibitors
|
US8377873B2
(en)
|
2006-10-24 |
2013-02-19 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
CA2667266C
(en)
|
2006-10-24 |
2015-11-24 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
AU2007309544B2
(en)
|
2006-10-24 |
2012-05-31 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
CA2667032A1
(en)
|
2006-10-27 |
2008-05-15 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
BRPI0718161A2
(pt)
|
2006-10-27 |
2013-11-26 |
Merck & Co Inc |
Composto, composição farmacêutica, e, uso do composto.
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
US8101595B2
(en)
|
2006-12-20 |
2012-01-24 |
Istituto di Ricerche di Biologia Molecolare P. Angletti SpA |
Antiviral indoles
|
CN101611025A
(zh)
|
2006-12-22 |
2009-12-23 |
先灵公司 |
5,6-环化的吲哚衍生物及其使用方法
|
WO2008082488A1
(en)
|
2006-12-22 |
2008-07-10 |
Schering Corporation |
4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
|
US8557848B2
(en)
*
|
2006-12-22 |
2013-10-15 |
Merck Sharp & Dohme Corp. |
4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
|
US7541351B2
(en)
*
|
2007-01-11 |
2009-06-02 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
US7541352B2
(en)
*
|
2007-02-02 |
2009-06-02 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
US7517872B2
(en)
|
2007-02-22 |
2009-04-14 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
WO2008106130A2
(en)
*
|
2007-02-26 |
2008-09-04 |
Achillion Pharmaceuticals, Inc. |
Tertiary amine substituted peptides useful as inhibitors of hcv replication
|
EP2144604B1
(en)
|
2007-02-28 |
2011-09-21 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of chronic viral hepatitis C using RO 113-0830
|
US7998951B2
(en)
*
|
2007-03-05 |
2011-08-16 |
Bristol-Myers Squibb Company |
HCV NS5B inhibitors
|
EP2121694B1
(en)
*
|
2007-03-13 |
2014-07-16 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
|
US7541353B2
(en)
*
|
2007-03-14 |
2009-06-02 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
US7538102B2
(en)
|
2007-03-14 |
2009-05-26 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
US7547690B2
(en)
|
2007-03-14 |
2009-06-16 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
US7521444B2
(en)
*
|
2007-03-14 |
2009-04-21 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
US7538103B2
(en)
*
|
2007-03-15 |
2009-05-26 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
ATE548044T1
(de)
|
2007-05-04 |
2012-03-15 |
Vertex Pharma |
Kombinationstherapie zur behandlung von hiv- infektionen
|
AU2008277440A1
(en)
*
|
2007-07-17 |
2009-01-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Macrocyclic indole derivatives for the treatment of hepatitis C infections
|
CA2699891C
(en)
|
2007-07-19 |
2013-10-22 |
Nigel Liverton |
Macrocyclic compounds as antiviral agents
|
US8143243B2
(en)
*
|
2007-08-09 |
2012-03-27 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
US7652004B2
(en)
*
|
2007-08-09 |
2010-01-26 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
US7642251B2
(en)
*
|
2007-08-09 |
2010-01-05 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
RU2010111551A
(ru)
|
2007-08-29 |
2011-10-10 |
Шеринг Корпорейшн (US) |
Замещенные индольные производные и способы их применения
|
AR068109A1
(es)
*
|
2007-08-29 |
2009-11-04 |
Schering Corp |
Derivados tetraciclicos de indol y una composicion farmaceutica
|
JP5258889B2
(ja)
|
2007-08-29 |
2013-08-07 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ウイルス感染症の治療のための2,3−置換アザインドール誘導体
|
AU2008295476B2
(en)
|
2007-08-29 |
2013-08-01 |
Merck Sharp & Dohme Corp. |
2, 3-Substituted Indole Derivatives for treating viral infections
|
US8765757B2
(en)
|
2007-11-16 |
2014-07-01 |
Merck Sharp & Dohme Corp. |
3-heterocyclic substituted indole derivatives and methods of use thereof
|
JP5416708B2
(ja)
|
2007-11-16 |
2014-02-12 |
メルク・シャープ・アンド・ドーム・コーポレーション |
3−アミノスルホニル置換インドール誘導体およびそれらの使用方法
|
US8129367B2
(en)
*
|
2007-11-21 |
2012-03-06 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
US8124601B2
(en)
|
2007-11-21 |
2012-02-28 |
Bristol-Myers Squibb Company |
Compounds for the treatment of Hepatitis C
|
AU2008338273B2
(en)
|
2007-12-19 |
2014-10-02 |
Boehringer Ingelheim International Gmbh |
Viral polymerase inhibitors
|
ES2389994T3
(es)
|
2007-12-24 |
2012-11-05 |
Janssen R&D Ireland |
Indoles macrocíclicos como inhibidores del virus de la hepatitis C
|
US8147818B2
(en)
*
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
KR20100126560A
(ko)
*
|
2008-03-27 |
2010-12-01 |
브리스톨-마이어스 스큅 컴퍼니 |
피롤리딘 융합된 인돌로벤자디아제핀 hcv ns5b 억제제
|
JP2011517673A
(ja)
*
|
2008-03-27 |
2011-06-16 |
ブリストル−マイヤーズ スクイブ カンパニー |
芳香族ヘテロ環縮合インドロベンザジアゼピンhcvns5b阻害剤
|
EP2276764B1
(en)
*
|
2008-03-27 |
2013-07-24 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis c
|
MX2010010245A
(es)
*
|
2008-03-27 |
2010-10-05 |
Bristol Myers Squibb Co |
Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a dioxolano y dioxolanona.
|
CN102014911A
(zh)
|
2008-04-28 |
2011-04-13 |
默沙东公司 |
Hcv ns3蛋白酶抑制剂
|
US8133884B2
(en)
*
|
2008-05-06 |
2012-03-13 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis C
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
US8901139B2
(en)
|
2008-06-13 |
2014-12-02 |
Merck Sharp & Dohme Corp. |
Tricyclic indole derivatives and methods of use thereof
|
TWI454476B
(zh)
*
|
2008-07-08 |
2014-10-01 |
Tibotec Pharm Ltd |
用作c型肝炎病毒抑制劑之巨環吲哚衍生物
|
RS52534B
(en)
|
2008-07-22 |
2013-04-30 |
Merck Sharp & Dohme Corp. |
MACROCYCLIC COMPOUNDS OF HINOXALINE AS HCV NS3 PROTEASE INHIBITORS
|
EP2324025A1
(en)
|
2008-08-11 |
2011-05-25 |
Smithkline Beecham Corporation |
Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
|
MX2011001663A
(es)
|
2008-08-11 |
2011-03-24 |
Glaxosmithkline Llc |
Derivados novedosos de adenina.
|
UA103195C2
(uk)
|
2008-08-11 |
2013-09-25 |
Глаксосмитклайн Ллк |
Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
|
UY32099A
(es)
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
KR20110096557A
(ko)
*
|
2008-12-10 |
2011-08-30 |
아칠리온 파르마세우티칼스 인코포레이티드 |
바이러스 복제의 억제제로서 4-아미노-4-옥소부타노일 펩티드 사이클릭 유사체
|
CN102245599B
(zh)
|
2008-12-10 |
2014-05-14 |
艾其林医药公司 |
作为病毒复制抑制剂的新的4-氨基-4-氧代丁酰基肽
|
WO2010072598A1
(en)
*
|
2008-12-22 |
2010-07-01 |
F. Hoffmann-La Roche Ag |
Heterocyclic antiviral compounds
|
EP2376088B1
(en)
|
2008-12-23 |
2017-02-22 |
Gilead Pharmasset LLC |
6-O-Substituted-2-amino-purine nucleoside phosphoramidates
|
EP2376514A2
(en)
|
2008-12-23 |
2011-10-19 |
Pharmasset, Inc. |
Nucleoside analogs
|
TW201031675A
(en)
|
2008-12-23 |
2010-09-01 |
Pharmasset Inc |
Synthesis of purine nucleosides
|
MX2011007195A
(es)
|
2009-01-07 |
2013-07-12 |
Scynexis Inc |
Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
|
WO2010093359A1
(en)
*
|
2009-02-11 |
2010-08-19 |
Bristol-Myers Squibb Company |
Compounds for the treatment of hepatitis c
|
US8143244B2
(en)
*
|
2009-02-26 |
2012-03-27 |
Bristol-Myers Squibb Company |
Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
|
ES2573088T3
(es)
|
2009-03-27 |
2016-06-06 |
Merck Sharp & Dohme Corp. |
Inhibidores de la replicación del virus de la hepatitis C
|
US20190127365A1
(en)
|
2017-11-01 |
2019-05-02 |
Merck Sharp & Dohme Corp. |
Inhibitors of hepatitis c virus replication
|
WO2010114896A1
(en)
*
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted indolo-pyridinone compounds
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
WO2011014487A1
(en)
|
2009-07-30 |
2011-02-03 |
Merck Sharp & Dohme Corp. |
Hepatitis c virus ns3 protease inhibitors
|
BR112012018904A2
(pt)
|
2010-02-10 |
2020-09-01 |
Glaxosmithkline Llc |
composto, adjuvante de vacina, composições imunogênica, de vacina e farmacêutica, e uso de um composto"
|
WO2011098451A1
(en)
|
2010-02-10 |
2011-08-18 |
Glaxosmithkline Llc |
Purine derivatives and their pharmaceutical uses
|
EP2545060B1
(en)
*
|
2010-03-09 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
|
UY33312A
(es)
|
2010-03-31 |
2011-10-31 |
Pharmasset Inc |
Fosforamidato de nucleosido de purina
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
UY33311A
(es)
|
2010-03-31 |
2011-10-31 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
JP5870098B2
(ja)
|
2010-06-24 |
2016-02-24 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
13−シクロヘキシル−3−メトキシ−6−[メチル−(2−{2−[メチル−(スルファモイル)−アミノ]−エトキシ}−エチル)−カルバモイル]−7H−インドロ−[2,1−a]−[2]−ベンズアゼピン−10−カルボン酸の製造
|
CA2812779A1
(en)
*
|
2010-09-29 |
2012-04-19 |
Merck Sharp & Dohme Corp. |
Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
|
US8841275B2
(en)
|
2010-11-30 |
2014-09-23 |
Gilead Pharmasset Llc |
2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
|
CA2821340A1
(en)
|
2010-12-30 |
2012-07-05 |
Enanta Pharmaceuticals, Inc. |
Phenanthridine macrocyclic hepatitis c serine protease inhibitors
|
WO2012092409A2
(en)
|
2010-12-30 |
2012-07-05 |
Enanta Phararmaceuticals, Inc |
Macrocyclic hepatitis c serine protease inhibitors
|
WO2012122716A1
(en)
|
2011-03-17 |
2012-09-20 |
Merck Sharp & Dohme Corp. |
Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
|
US10201584B1
(en)
|
2011-05-17 |
2019-02-12 |
Abbvie Inc. |
Compositions and methods for treating HCV
|
SI2709613T2
(sl)
|
2011-09-16 |
2020-12-31 |
Gilead Pharmasset LLC c/o Gilead Sciences, Inc. |
Postopki za zdravljenje HCV
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
GB2506086A
(en)
|
2011-10-21 |
2014-03-19 |
Abbvie Inc |
Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
|
CA2811250C
(en)
|
2011-10-21 |
2015-08-11 |
Abbvie Inc. |
Methods for treating hcv
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
WO2013163239A1
(en)
*
|
2012-04-26 |
2013-10-31 |
Francis Xavier Tavares |
Synthesis of lactams
|
KR20150038122A
(ko)
*
|
2012-07-18 |
2015-04-08 |
브리스톨-마이어스 스퀴브 홀딩스 아일랜드 |
(4bS,5aR)-12-시클로헥실-N-(N,N-디메틸술파모일)-3-메톡시-5a-((1R,5S)-3-메틸-3,8-디아자비시클로[3.2.1]옥탄-8-카르보닐)-4b,5,5a,6-테트라히드로벤조[3,4]시클로프로파[5,6]아제피노[1,2-a]인돌-9-카르복스아미드의 제조를 위한 신규 방법 및 중간체
|
WO2014110687A1
(en)
|
2013-01-16 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
|
SG11201506021XA
(en)
|
2013-01-31 |
2015-08-28 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
WO2014121417A1
(en)
*
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
WO2014121418A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
WO2014121416A1
(en)
*
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
WO2014144087A1
(en)
|
2013-03-15 |
2014-09-18 |
Achillion Pharmaceuticals, Inc. |
Sovaprevir polymorphs and methods of manufacture thereof
|
WO2014145600A1
(en)
|
2013-03-15 |
2014-09-18 |
Achillion Pharmaceuticals, Inc. |
Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
|
US9006423B2
(en)
|
2013-03-15 |
2015-04-14 |
Achillion Pharmaceuticals Inc. |
Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
|
MX2016002185A
(es)
|
2013-08-27 |
2016-06-06 |
Gilead Pharmasset Llc |
Formulacion combinada de dos compuestos antivirales.
|
WO2015061407A1
(en)
*
|
2013-10-24 |
2015-04-30 |
Francis Xavier Tavares |
Process for synthesis of lactams
|
WO2015103490A1
(en)
|
2014-01-03 |
2015-07-09 |
Abbvie, Inc. |
Solid antiviral dosage forms
|
ES2655940T3
(es)
|
2014-02-20 |
2018-02-22 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Derivados de pirrolo[3,2-d]pirimidina como inductores de interferón humano
|
CN107108628A
(zh)
|
2014-11-13 |
2017-08-29 |
葛兰素史密丝克莱恩生物有限公司 |
可用于治疗变应性疾病或其它炎性病症的腺嘌呤衍生物
|
PE20181297A1
(es)
|
2015-12-03 |
2018-08-07 |
Glaxosmithkline Ip Dev Ltd |
Dinucleotidos de purino ciclico como moduladores de sting
|
IL285702B
(en)
|
2016-04-07 |
2022-09-01 |
Glaxosmithkline Ip Dev Ltd |
Heterocyclic amides are useful as protein modulators
|
WO2017175156A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators
|
US11192914B2
(en)
|
2016-04-28 |
2021-12-07 |
Emory University |
Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
|
KR20200035234A
(ko)
|
2017-05-12 |
2020-04-02 |
마발론 테라퓨틱스 리미티드 |
그룹 ii 대사성 글루타메이트 수용체의 알로스테릭 조절제로서의 치환된 헤테로사이클릭 화합물
|
TW201927771A
(zh)
|
2017-10-05 |
2019-07-16 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
可作為蛋白質調節劑之雜環醯胺及其使用方法
|
BR112020006780A2
(pt)
|
2017-10-05 |
2020-10-06 |
Glaxosmithkline Intellectual Property Development Limited |
moduladores do estimulador de genes do interferon (sting)
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
US20220251079A1
(en)
|
2019-05-16 |
2022-08-11 |
Stingthera, Inc. |
Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
|
WO2020232375A1
(en)
|
2019-05-16 |
2020-11-19 |
Silicon Swat, Inc. |
Oxoacridinyl acetic acid derivatives and methods of use
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|